159 related articles for article (PubMed ID: 29123407)
1. Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.
Xie H; Xie B; Liu C; Wang J; Xu Y
Onco Targets Ther; 2017; 10():5089-5097. PubMed ID: 29123407
[TBL] [Abstract][Full Text] [Related]
2. Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis.
Luo R; Chen Y; Ran K; Jiang Q
Transl Androl Urol; 2020 Dec; 9(6):2713-2722. PubMed ID: 33457243
[TBL] [Abstract][Full Text] [Related]
3. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract][Full Text] [Related]
4. PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
Wang Y; Dai B
Int J Clin Exp Med; 2015; 8(4):5430-7. PubMed ID: 26131120
[TBL] [Abstract][Full Text] [Related]
5. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.
Zhang L; Wu B; Zha Z; Zhao H; Jiang Y; Yuan J
World J Surg Oncol; 2018 Jul; 16(1):124. PubMed ID: 29970100
[TBL] [Abstract][Full Text] [Related]
6. Different predictive values of microvessel density for biochemical recurrence among different PCa populations: A systematic review and meta-analysis.
Jiang J; Li J; Xiong X; Zhang S; Tan D; Yang L; Wei Q
Cancer Med; 2023 Feb; 12(3):2166-2178. PubMed ID: 35933720
[TBL] [Abstract][Full Text] [Related]
7. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
Liu R; Zhou J; Xia S; Li T
Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PTEN Gene Loss as a Possible Prognostic Marker for Prostate Cancer.
Patel DM; Varma PK; Kazi MM; Patel PS; Trivedi PJ
J Assoc Genet Technol; 2022; 48(2):63-67. PubMed ID: 35661650
[TBL] [Abstract][Full Text] [Related]
9. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
Breen KJ; O'Neill A; Murphy L; Fan Y; Boyce S; Fitzgerald N; Dorris E; Brady L; Finn SP; Hayes BD; Treacy A; Barrett C; Aziz MA; Kay EW; Fitzpatrick JM; Watson RWG
Prostate; 2017 Sep; 77(12):1288-1300. PubMed ID: 28726241
[TBL] [Abstract][Full Text] [Related]
10. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
[No Abstract] [Full Text] [Related]
11. PTEN in kidney cancer: A review and meta-analysis.
Que WC; Qiu HQ; Cheng Y; Liu MB; Wu CY
Clin Chim Acta; 2018 May; 480():92-98. PubMed ID: 29408173
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Diao W; Cao Y; Su D; Jia Z
BJU Int; 2021 Feb; 127(2):153-163. PubMed ID: 32979229
[TBL] [Abstract][Full Text] [Related]
13. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
[TBL] [Abstract][Full Text] [Related]
14. Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.
Sun JX; Liu CQ; Zhong XY; Xu JZ; An Y; Xu MY; Hu J; Zhang ZB; Xia QD; Wang SG
Front Oncol; 2022; 12():887854. PubMed ID: 35615153
[TBL] [Abstract][Full Text] [Related]
15. Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis.
Zhang LJ; Wu B; Zha ZL; Qu W; Zhao H; Yuan J; Feng YJ
BMC Urol; 2018 Feb; 18(1):5. PubMed ID: 29390991
[TBL] [Abstract][Full Text] [Related]
16. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis.
Tan P; Wei S; Yang L; Tang Z; Cao D; Liu L; Lei J; Fan Y; Gao L; Wei Q
Sci Rep; 2016 Jul; 6():29106. PubMed ID: 27384548
[TBL] [Abstract][Full Text] [Related]
17. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
18. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
[TBL] [Abstract][Full Text] [Related]
20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
